Logo

GOVX

GeoVax Labs, Inc.

GOVX

GeoVax Labs, Inc. • NASDAQ
$0.41 ▲ 2.77% (+0.01)
Market Cap $10.43 M
52w High $2.77
52w Low $0.37
Dividend Yield 0%
P/E -0.32
Volume 213.93K
Outstanding Shares 25.36M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 ▼ $6.356M ▲ $-6.319M ▼ 0% ▲ $-0.31 ▲ $-6.302M ▼
Q2-2025 $852.282K ▼ $6.271M ▼ $-5.37M ▼ -630.048% ▼ $-0.35 ▲ $-5.353M ▼
Q1-2025 $1.637M ▲ $7.025M ▼ $-5.358M ▲ -327.312% ▲ $-0.45 ▲ $-5.341M ▲
Q4-2024 $864.415K ▼ $9.187M ▲ $-8.263M ▼ -955.866% ▼ $-0.78 ▲ $-8.241M ▼
Q3-2024 $2.789M $8.644M $-5.815M -208.478% $-0.91 $-5.771M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $5.009M ▲ $6.731M ▲ $1.824M ▼ $4.907M ▲
Q2-2025 $3.094M ▼ $5.35M ▼ $2.529M ▼ $2.821M ▼
Q1-2025 $7.439M ▲ $10.833M ▲ $2.935M ▼ $7.898M ▲
Q4-2024 $5.507M ▼ $8.156M ▼ $3.107M ▲ $5.049M ▼
Q3-2024 $8.593M $11.112M $2.608M $8.504M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-6.319M ▼ $-6.212M ▼ $0 ▲ $8.127M ▲ $1.915M ▲ $-6.212M ▼
Q2-2025 $-5.37M ▼ $-4.334M ▲ $-10.718K ▲ $209 ▼ $-4.345M ▼ $-4.334M ▲
Q1-2025 $-5.358M ▲ $-5.966M ▲ $-16.894K ▼ $7.914M ▲ $1.932M ▲ $-5.966M ▲
Q4-2024 $-8.263M ▼ $-7.754M ▲ $0 ▲ $4.668M ▼ $-3.086M ▼ $-7.754M ▲
Q3-2024 $-5.815M $-9.297M $-20.653K $16.349M $7.031M $-9.318M

Revenue by Products

Product Q1-2022
NIAID Grant
NIAID Grant
 $0 ▲

Five-Year Company Overview

Income Statement

Income Statement GeoVax is still a pure development-stage biotech: it has essentially no product revenue yet and runs consistent operating losses. The losses reflect spending on research, clinical trials, and overhead rather than any profitability issues in an existing business. Per‑share losses have been sizable, which also reflects share count changes over time. Overall, the income statement tells a story of a company investing ahead of any commercial payoff, with the usual uncertainty around if and when future products will generate meaningful sales.

Balance Sheet

Balance Sheet The balance sheet is very simple and relatively light: most assets are held as cash, with no reported financial debt. Equity is positive but modest, which suggests a limited financial cushion and dependence on external funding to support ongoing research and trials. The long history of reverse stock splits points to meaningful past dilution and pressure on the share price. Financially, GeoVax looks lean and clean in terms of debt, but also financially fragile if access to new capital were to tighten.

Cash Flow

Cash Flow Cash flows show regular outflows from operations, reflecting the cost of running a clinical‑stage biotech without revenue. There is no meaningful capital spending, so almost all cash usage is tied to people, trials, and overhead. Free cash flow is negative, which means the company must periodically raise capital through equity or other means to keep funding its programs. Sustainability of the current burn rate depends heavily on continued access to financing and on managing spending as trials advance or pivot.

Competitive Edge

Competitive Edge GeoVax’s competitive angle rests on its proprietary vaccine and cancer‑therapy platforms rather than on market share today. The MVA‑VLP vaccine platform aims to deliver broader and more durable immune responses, especially valuable for immunocompromised patients and emerging infections. Gedeptin offers a targeted cancer approach focused initially on difficult head and neck tumors, with potential in other solid cancers. At the same time, the company operates in highly competitive spaces—vaccines and oncology—where large pharmaceutical firms and other biotechs also chase similar indications, so strong clinical data and partnerships will be essential to stand out.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. The MVA‑VLP platform is designed to trigger both antibody and T‑cell responses, support multiple viral targets, and work with more practical storage and distribution, which is attractive for global use. Gedeptin aims to convert a relatively harmless drug into a powerful anti‑cancer agent directly inside tumors, potentially limiting side effects and combining well with modern immunotherapies. The pipeline extends beyond COVID‑19 into Mpox, smallpox, hemorrhagic fevers, malaria, and Zika, and management is also working on better manufacturing methods and exploring AI‑driven development, all of which could increase long‑term optionality if the science translates into strong trial outcomes.

Summary

GeoVax is a high‑risk, early‑stage biotech focused on innovative vaccine and cancer‑therapy platforms rather than an existing commercial business. Financial statements show no revenue, steady losses, negative cash flow, and a small but debt‑free balance sheet, implying reliance on ongoing external funding. On the positive side, the company holds differentiated technologies, clear focus areas (immunocompromised patients, Mpox/smallpox, solid tumors), and government and academic collaborations that add credibility. The main uncertainties lie in clinical trial success, regulatory outcomes, competitive pressure from larger players, and the company’s ability to fund itself until any products can reach the market.